N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms.
Erica NeillSusan L RossellCaitlin O B YollandDenny MeyerCherrie GalletlyAnthony HarrisDan J SiskindMichael BerkKiymet BozaogluFrances DarkOlivia M DeanPaul S FrancisDennis LiuAndrea PhillipouJerome SarrisDavid J CastlePublished in: Schizophrenia bulletin (2022)
NAC did not significantly improve schizophrenia symptoms, cognition, or quality of life in treatment-resistant patients taking clozapine. This trial was registered with "Australian and New Zealand Clinical Trials" on the 30 May, 2016 (Registration Number: ACTRN12615001273572).
Keyphrases
- clinical trial
- double blind
- phase iii
- bipolar disorder
- phase ii
- transcription factor
- end stage renal disease
- study protocol
- open label
- newly diagnosed
- ejection fraction
- chronic kidney disease
- placebo controlled
- prognostic factors
- sleep quality
- cancer therapy
- patient reported outcomes
- white matter
- drug delivery
- physical activity
- patient reported